Beyond the genome and proteome: targeting protein modifications in cancer

Hart, 2010, Glycomics hits the big time, Cell, 143, 672, 10.1016/j.cell.2010.11.008 Schachter, 2009, Glycosylation diseases: quo vadis?, Biochim Biophys Acta, 1792, 925, 10.1016/j.bbadis.2008.11.002 Song, 2010, The bisecting GlcNAc on N-glycans inhibits growth factor signaling and retards mammary tumor progression, Cancer Res, 70, 3361, 10.1158/0008-5472.CAN-09-2719 Apweiler, 1999, On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database, Biochim Biophys Acta, 1473, 4, 10.1016/S0304-4165(99)00165-8 Lis, 1993, Protein glycosylation. Structural and functional aspects, Eur J Biochem, 218, 1, 10.1111/j.1432-1033.1993.tb18347.x Walsh, 1990, Effect of the carbohydrate moiety on the secondary structure of beta 2-glycoprotein. I. Implications for the biosynthesis and folding of glycoproteins, Biochemistry, 29, 6250, 10.1021/bi00478a020 Lasky, 1992, Selectins: interpreters of cell-specific carbohydrate information during inflammation, Science, 258, 964, 10.1126/science.1439808 Homans, 1987, Solution conformations of N-linked oligosaccharides, Biochemistry, 26, 6571, 10.1021/bi00395a001 Haltiwanger, 2002, Modulation of receptor signaling by glycosylation: fringe is an O-fucose-beta1,3-N-acetylglucosaminyltransferase, Biochim Biophys Acta, 1573, 328, 10.1016/S0304-4165(02)00400-2 Brockhausen, 2006, Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions, EMBO Rep, 7, 599, 10.1038/sj.embor.7400705 Adamczyk, 2012, Glycans as cancer biomarkers, Biochim Biophys Acta, 1820, 1347, 10.1016/j.bbagen.2011.12.001 Korekane, 2012, Development of an antibody-lectin enzyme immunoassay for fucosylated α-fetoprotein, Biochim Biophys Acta, 1820, 1405, 10.1016/j.bbagen.2011.12.015 Rambaruth, 2011, Cell surface glycan-lectin interactions in tumor metastasis, Acta Histochem, 113, 591, 10.1016/j.acthis.2011.03.001 Dennis, 1999, Glycoprotein glycosylation and cancer progression, Biochim Biophys Acta, 1473, 21, 10.1016/S0304-4165(99)00167-1 Contessa, 2010, Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy, Clin Cancer Res, 16, 3205, 10.1158/1078-0432.CCR-09-3331 Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA: Control of mucin-type O-glycosylation—a classification of the polypeptide GalNAc-transferase gene family. Glycobiology [Epub ahead of print]. Burchell, 2011, O-linked glycosylation in the mammary gland: changes that occur during malignancy, J Mammary Gland Biol Neoplasia, 6, 355, 10.1023/A:1011331809881 Brooks, 2000, The involvement of Helix pomatia lectin (HPA) binding N-acetylgalactosamine glycans in cancer progression, Histol Histopathol, 15, 143 Blixt, 2011, Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis, Breast Cancer Res, 13, R25, 10.1186/bcr2841 Kufe, 2009, Mucins in cancer: function, prognosis and therapy, Nat Rev Cancer, 9, 874, 10.1038/nrc2761 Slawson, 2008, A mitotic GlcNAcylation/phosphorylation signaling complex alters the posttranslational state of the cytoskeletal protein vimentin, Mol Biol Cell, 19, 4130, 10.1091/mbc.E07-11-1146 Copeland, 2008, Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity, Am J Physiol Endocrinol Metab, 295, E17, 10.1152/ajpendo.90281.2008 Laczy, 2009, Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system, Am J Physiol Heart Circ Physiol, 296, H13, 10.1152/ajpheart.01056.2008 Lazarus, 2009, O-GlcNAc cycling: implications for neurodegenerative disorders, Int J Biochem Cell Biol, 41, 2134, 10.1016/j.biocel.2009.03.008 Slawson, 2011, O-GlcNAc signalling: implications for cancer cell biology, Nat Rev Cancer, 11, 678, 10.1038/nrc3114 Rambaruth, 2012, The lectin Helix pomatia agglutinin recognises O-GlcNAc containing glycoproteins in human breast cancer, Glycobiology, 22, 839, 10.1093/glycob/cws051 Lazarus, 2011, Structure of human O-GlcNAc transferase and its complex with a peptide substrate, Nature, 469, 564, 10.1038/nature09638 Heindl, 2011, Cation-pi interactions induce kinking of a molecular hinge in the RNA polymerase bridge-helix domain, Biochem Soc Trans, 39, 31, 10.1042/BST0390031 Haltiwanger, 1998, Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-d-glucopyranosylidene)amino-N-phenylcarbamate, J Biol Chem, 273, 3611, 10.1074/jbc.273.6.3611 Dorfmueller, 2011, Substrate and product analogues as human O-GlcNAc transferase inhibitors, Amino Acids, 40, 781, 10.1007/s00726-010-0688-y Levine, 2010, The control of the metabolic switch in cancer by oncogenes and tumor suppressor genes, Science, 330, 1340, 10.1126/science.1193494 Julien, 2011, Inside the human cancer tyrosine phosphatome, Nat Rev Cancer, 11, 35, 10.1038/nrc2980 Haystead, 1989, Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism, Nature, 337, 78, 10.1038/337078a0 Slee, 2010, Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo, Proc Natl Acad Sci USA, 107, 1979, 10.1073/pnas.1005165107 Arif, 2011, Protein lysine acetylation in cellular function and its role in cancer manifestation, Biochim Biophys Acta, 1799, 702, 10.1016/j.bbagrm.2010.10.002 Wagner, 2010, Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy, Clin Epigenet, 1, 117, 10.1007/s13148-010-0012-4 Duncan, 2011, Errors in erasure: links between histone lysine methylation removal and disease, Prog Drug Res, 67, 69 Abdollahi, 2010, Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy, Drug Resist Updat, 13, 16, 10.1016/j.drup.2009.12.001 Ischiropoulos, 2009, Protein tyrosine nitration—an update, Arch Biochem Biophys, 484, 117, 10.1016/j.abb.2008.10.034 Osoata, 2010, Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2, Biochem Biophys Res Commun, 384, 366, 10.1016/j.bbrc.2009.04.128 Myllyhrju, 2009, HIF prolyl 4-hydroxylases and their potential as drug targets, Curr Pharm Des, 15, 3878, 10.2174/138161209789649457 Slaun, 2010, The intracellular dynamic of protein palmitoylation, J Cell Biol, 191, 1229, 10.1083/jcb.201008160 Cuiffo, 2010, Palmitoylation of oncogenic NRAS is essential for leukemogenesis, Blood, 115, 3598, 10.1182/blood-2009-03-213876 Yeh, 2000, Ubiquitin-like proteins: new wines in new bottle, Gene, 248, 1, 10.1016/S0378-1119(00)00139-6 Bosanac, 2010, Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB signaling, Mol Cell, 40, 548, 10.1016/j.molcel.2010.10.009 Jakubowiak, 2012, Phase I trial of anti-CS1 monoclonal antibody Elotuzumab in combination with Bortezomib in the treatment of relapsed/refractory multiple myeloma, J Clin Oncol, 10.1200/JCO.2011.37.7069 Bedford, 2011, Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets, Nat Rev Drug Discov, 10, 29, 10.1038/nrd3321